Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
Marcin Cieślak, Marta Słowianek
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 812-812
Open Access | Times Cited: 20

Showing 20 citing articles:

The Magic Methyl and Its Tricks in Drug Discovery and Development
Pedro de Sena Murteira Pinheiro, Lucas Silva Franco, Carlos Alberto Manssour Fraga
Pharmaceuticals (2023) Vol. 16, Iss. 8, pp. 1157-1157
Open Access | Times Cited: 48
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 10
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 578-578
Open Access | Times Cited: 7
Small molecule induced STING degradation facilitated by the HECT ligase HERC4
Merve Mutlu, Isabel Schmidt, Andrew I. Morrison, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
BTK inhibitors: past, present, and future
Allison Cool, Tiffany Nong, Skye Montoya, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 8, pp. 691-707
Closed Access | Times Cited: 7
Cellular parameters shaping pathways of targeted protein degradation
A.G. Cardno, Bryony G. Kennedy, Catherine Lindon
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
A Multicomponent Reaction-Based Platform Opens New Avenues in Aryl Hydrocarbon Receptor Modulation
Pau Nadal Rodríguez, Frederick Hartung, Marina Pedrola, et al.
ACS Central Science (2025)
Open Access
Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors
K. Sasikumar, Yawen Wang, Yanyan Han, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Exploiting E3 Ligases for Lung Cancer Therapy: The Promise of DCAF-PROTACs
Md Sadique Hussain, Lina Eltaib, Amita Rana, et al.
Pathology - Research and Practice (2025), pp. 156001-156001
Closed Access
PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
Caterina Mancarella, Andrea Morrione, Katia Scotlandi
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16346-16346
Open Access | Times Cited: 9
Inhibitors and PROTACs of CDK2: challenges and opportunities
Yangjie Zeng, Xiaodong Ren, Pengyao Jin, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1125-1148
Closed Access | Times Cited: 3
Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations
Zhijie Wang, Xun Lu, Canlin Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116237-116237
Closed Access | Times Cited: 2
Development of PROTACS degrading KRAS and SOS1
Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 8, pp. 1257-1264
Open Access | Times Cited: 2
PROTAC‐Mediated HDAC7 Protein Degradation Unveils Its Deacetylase‐Independent Proinflammatory Function in Macrophages
Kailibinuer Kadier, Tian Niu, Baoli Ding, et al.
Advanced Science (2024)
Open Access | Times Cited: 2
Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity
Mark Mabanglo, Brian C. Wilson, Mahmoud Noureldin, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Discovery of a selective TC-PTP degrader for cancer immunotherapy
Jinmin Miao, Jiajun Dong, Yiming Miao, et al.
Chemical Science (2023) Vol. 14, Iss. 44, pp. 12606-12614
Open Access | Times Cited: 6
Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors
K. Sasikumar, Yawen Wang, Yanyan Han, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Exploring Degradation of Intrinsically Disordered Protein Yes-Associated Protein Induced by Proteolysis TArgeting Chimeras
Chen Zhou, Chunbao Sun, Miao Huang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 15168-15198
Closed Access | Times Cited: 1
Exploring Degradation of Intrinsically Disordered Protein YAP induced by PROTACs
Chen Zhou, Chunbao Sun, Liya Pi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Proteolysis-targeting vaccines (PROTAVs) for robust tumor combination immunotherapy
Qiyan Wang, Ting Su, Furong Cheng, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1

Scroll to top